Phase 3 Trial to Assess TTFields plus Taxol in Platinum-resistant Ovarian Cancer Patients

Phase 3 Trial to Assess TTFields plus Taxol in Platinum-resistant Ovarian Cancer Patients
A Phase 3 clinical trial will investigate the impact of adding Tumor Treating Fields (TTFields), a method that uses electric fields to disrupt cell division, to Taxol (paclitaxel) for the treatment of ovarian cancer patients who are resistant to platinum-based chemotherapy. Details of the clinical trial will be presented June 4 at the 2018 American Society of Clinical

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *